Literature DB >> 15373912

Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.

S Lee1, C-A Almeida, M A H French, P Price.   

Abstract

HIV-1 infected patients adherent to HAART and displaying stable increases in CD4 T-cell counts differ in their control of HIV replication and one might expect this to reflect depressed immune function. The importance of virological control in functional immune reconstitution was investigated in HIV-1 infected patients who maintained high or undetectable plasma HIV RNA levels over 2-4 years on HAART (discordant and complete responders, respectively). Immunocompetence and immune activation were assessed directly ex vivo and after a short period of culture, as HIV replication in cultures from viraemic patients may artificially depress responses. Expression of cytokine (interferon-gamma, interleukin-5) and chemokine receptor (CCR5, CRTH2) mRNA were determined and soluble CD30 and NO(2) (-)/NO(3) (-) were measured in sera. Unstimulated cells from all patients had low levels of IFNgamma mRNA relative to uninfected controls. Discordant responders had more IFNgamma, IL-5 and CCR5 mRNA in mitogen-stimulated PBMC than complete responders, where the difference could be attributed to CD8-T-cells. Serum NO(2) (-)/NO(3) (-) levels were significantly higher in all patients than controls, with no difference between complete and discordant responders. Serum CD30 levels were significantly higher in discordant responders. These data indicate a persistent immune deficit in immune reconstituted patients irrespective of HIV viral load and associate persistent viral replication with lymphocyte activation, probably involving CD8 T-cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373912      PMCID: PMC1809174          DOI: 10.1111/j.1365-2249.2004.02589.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.

Authors:  Steven G Deeks; Rebecca Hoh; Robert M Grant; Terri Wrin; Jason D Barbour; Amy Narvaez; Denise Cesar; Ken Abe; Mary Beth Hanley; Nicholas S Hellmann; Christos J Petropoulos; Joseph M McCune; Marc K Hellerstein
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

Review 2.  Nitric oxide and bone.

Authors:  R J van't Hof; S H Ralston
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

3.  Effect of highly active antiretroviral therapy on expression of interleukin-10 and interleukin-12 in HIV-infected patients.

Authors:  Y Taoufik; I Peguillet; M G de Goër; M Lambert; B Gubler; A Trylesinski; J F Delfraissy; O Lantz
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-01       Impact factor: 3.731

4.  Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.

Authors:  D Mathez; P Bagnarelli; I Gorin; C Katlama; G Pialoux; G Saimot; P Tubiana; P De Truchis; J P Chauvin; R Mills; R Rode; M Clementi; J Leibowitch
Journal:  Antivir Ther       Date:  1997-07

5.  Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy.

Authors:  N M Keane; P Price; S F Stone; M John; R J Murray; M A French
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

6.  Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy.

Authors:  N Imami; C Antonopoulos; G A Hardy; B Gazzard; F M Gotch
Journal:  AIDS Res Hum Retroviruses       Date:  1999-11-20       Impact factor: 2.205

7.  Close link between CD4+ and CD8+ T cell proliferation defects in patients with human immunodeficiency virus disease and relationship to extended periods of CD4+ lymphopenia.

Authors:  Scott F Sieg; Jonathan B Mitchem; Douglas A Bazdar; Michael M Lederman
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

8.  An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy.

Authors:  N M Keane; P Price; S Lee; S F Stone; M A French
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

9.  Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

Authors:  C A Stoddart; T J Liegler; F Mammano; V D Linquist-Stepps; M S Hayden; S G Deeks; R M Grant; F Clavel; J M McCune
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

10.  Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.

Authors:  N M Keane; P Price; S Lee; C A Almeida; S F Stone; I James; M A French
Journal:  HIV Med       Date:  2004-11       Impact factor: 3.180

View more
  2 in total

1.  A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.

Authors:  Patricia Price; Niamh M Keane; Silvia Lee; Andrew F Y Lim; Elizabeth J McKinnon; Martyn A French
Journal:  Immunology       Date:  2006-06-22       Impact factor: 7.397

2.  Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques.

Authors:  Kenny L Lin; Nancy A Twenhafel; John H Connor; Kathleen A Cashman; Joshua D Shamblin; Ginger C Donnelly; Heather L Esham; Carly B Wlazlowski; Joshua C Johnson; Anna N Honko; Miriam A Botto; Judy Yen; Lisa E Hensley; Arthur J Goff
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.